Drug Database
Back to search

Poland· PL-100165034

Bleomedac

A bleomycin product containing bleomycini sulfas, registered in Poland by medac Gesellschaft fuer klinische Spezialpraeparate mbH. The same ATC class is registered in 15 of our 19 countries.

ATC L01DC01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedBleomedacATCL01DC01REGISTER NO.PL-100165034PACKS LISTED4CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about bleomycini sulfasAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Bleomycin is registered in 15 of 19 countries.

Countries holding a registration under ATC L01DC01 (bleomycin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search bleomycin products by name

Bleomycin · ATC L01DC01

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Bleomycini sulfas
Manufacturer
medac Gesellschaft fuer klinische Spezialpraeparate mbH
Country
Poland (PL)
ATC code
L01DC01
ATC class
Bleomycin
Defined daily dose
3 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 4

  • gtin
    05909990946983
  • gtin
    05909990924745
  • gtin
    05909991341466
  • gtin
    05909991341473

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

212 interactions on record for bleomycin.

Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check bleomycin against other medicinesHow interaction checks work

Bleomycin · interactions on record

212 records

  • 33 severe
  • 105 moderate
  • 15 minor
  • 59 info

Most severe, free to view

  • CladribineL01BB04severe
  • Brentuximab vedotinL01FX05severe
  • Brentuximab vedotinL01XC12severe
  • Talimogene laherparepvecL01XL02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Bleomycin in 5 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bleomycin products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

  • Belgium · Bleomycine Hikma
  • Germany · Bleomedac
  • Estonia · Bleomycin Medac
  • Finland · Bleomycin Baxter
  • France · Bleomycine Bellon
  • Italy · Bleoprim
  • Lithuania · Bleomycin Medac
  • Luxembourg · Bleomycine Hikma
  • Latvia · Bleomycin Medac
  • Portugal · Bleocin
  • Slovakia · Bleomedac

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f3139999-cee3-41d7-a5ad-6210fa8985f3
GET /v1/drugs/f3139999-cee3-41d7-a5ad-6210fa8985f3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania roztworu do wstrzykiwań",
  "source": "urpl",
  "strength": "15000 IU/fiolkę",
  "packaging": "05909990946983 ¦ Lz ¦ 53263\n1 fiol. 10 ml\n05909990924745 ¦ Lz ¦ 71696\n10 fiol. 10 ml\n05909991341466 ¦ Lz ¦ Skasowane ¦ 123939\n1 fiol. 20 ml\n05909991341473 ¦ Lz ¦ Skasowane ¦ 123940\n10 fiol. 20 ml",
  "substance": "Bleomycini sulfas 15000 j.m./fiolkę",
  "common_name": "Bleomycini sulfas",
  "pl_product_id": "100165034",
  "pozwolenie_nr": "18924",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about bleomycin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console